ST Kaiwang announced that from July 13 to 14, 2026, the cumulative deviation value of the closing price increase of the company's stock exceeded 20% for two consecutive trading days, which was an abnormal fluctuation. The company's net profit for 2023 to 2025 was - 1,690 million yuan, - 1,193 million yuan, and - 563 million yuan, respectively. There is uncertainty about future profit. The holding subsidiary plans to acquire a portion of Jinbaihui Biotech's shares. The company's 2025 revenue was 50.1763 million yuan, net profit - 1.072,200 yuan. The cooperation is still in the intention stage, and there is uncertainty. In addition, the company has been subject to other risk warnings due to audit report issues. If the relevant regulations are not met, stocks will be subject to delisting risk warnings.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.